)
)
)
Astrizi Bio
Astrizi Bio is a preclinical stage biopharmaceutical company developing orally available mitochondrial modifiers for Cardiometabolic Disorders, Parkinson's Disease and Alzheimer's Disease.
We have completed preclinical studies for our lead asset AS-005 and are entering first-in-human studies in obese healthy volunteers in Q2 2026.
We have completed our CRO and site selection for the phase 1a/b study. The study is fully funded.
We are looking for partnerships to advance AS-005 beyond phase , as well as for our follow-on assets in Neurodegenerative Diseases.
Address
AtlantaGeorgia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)